COPD360social Community Exchange

This research study at the Medical University of South Carolina (MUSC) is for women with chronic obstructive pulmonary disease (COPD) and to evaluate any unmet care needs. If you are a woman with COPD, you may qualify to participate in this study.

If you are interested in participating? Please click here to learn more.

If you have any questions or would like to participate in this research study, please contact Jessica Madiraca at 856-399-1678 or madiraca@musc.edu.

MEDI3506 is a type of human antibody that is made in a laboratory. An antibody is a protein that is usually naturally produced by the immune system (the body's defense system).

MEDI3506 can bind to, and block the actions of, a substance produced by the body called IL-33†. FRONTIER 4 is a clinical study being carried out in patients with COPD and chronic bronchitis. The study is being conducted to see if a treatment called MEDI3506 can provide benefit to patients with COPD.

To be considered for this study, you must:

• Have COPD
• Are a current or ex-smoker
• Have experienced 1 or more exacerbations (where symptoms are much worse than usual) in the past 2 years
• Are between 40 and 80 years old
• Frequent cough and/or mucus production

During the study, you will be asked to attend appointments that may include:

• Physical examinations
• Lung function tests
• Tests such as blood and urine samples and heart tests (ECG, ECHO*)
• CT† scan
• Collection of nasal tissue and sputum samples
• A well-being questionnaire

If you are interest in learning more, please Click here to complete an online pre-screener to see if there is a site in your area.

The State University of New York at Buffalo School of Nursing is conducting a survey about Mindfulness Knowledge and Practice Research for people living with COPD. It should take about 15 minutes of your time, and we will give you a $20.00 electronic Walmart Gift Card after you complete the survey.

If interested, please connect directly to the survey using this link. Enter the Code "FMPK7NKNC" when prompted.

At the end of the survey, please let us know whether or not you want to be contacted for a Zoom Interview (30-60 minutes). We will randomly select 10 participants for an interview on your experiences with mindfulness and how it may impact your COPD management. We will give you an additional gift card for doing the interview.

Learn more about ALIENTO, a clinical research study evaluating an investigational medication to see if it will reduce the rate of severe COPD exacerbations (flare-ups) in comparison with placebo over a 52-week treatment period.

Important: This investigational medication (or placebo, depending on which study group you are randomly assigned to) will be taken in addition to your regular standard-of-care COPD maintenance therapy.

To be considered for this study, you must:

• Be 40 years of age or older
• Have a medical diagnosis of COPD
• Be a current or ex-smoker with a minimum of 10 pack-year history (e.g., 20 cigarettes/day for 10 years)
• Over the past two years, have experienced 2 or more moderate or severe exacerbations (flare-ups) occurring within a 12-month period

Your health will be closely monitored by doctors and specialists throughout the duration of this study. Also, study-related visits and the investigational medication will be provided at no cost, and compensation for travel may be provided for completed study visits.

To learn more, please call 866-540-9740, or visit our study website at copdtrial4me.com to prescreen online.

We want to share an opportunity to participate in a Phase 3 clinical trial: AERIFY. This study seeks to assess the safety and effectiveness of Itepekimab in reducing COPD flares (exacerbations) in patients with persistent moderate-to-severe COPD symptoms.

You may be eligible to participate if you:

• Are 40-85 years of age and have a medical diagnosis of COPD
• Are a former or current smoker
• Currently take medications for COPD
• Have had one or more flare-ups in the last year requiring additional treatment and/or medical attention
• Have chronic bronchitis (a cough with phlegm for 3 months in the past year)

Study volunteers will potentially:

• Access a new investigational treatment option
• Receive study-related care from board-certified physicians at no cost to you or your insurance company
• Get compensated for your time and travel
• Understand your condition better
• Help others with COPD in the future

To learn more about the study and see if you may qualify, click here:

https://www.trialspark.com/trial/copd

The NOTUS Study is looking for volunteers with moderate to severe COPD to participate. NOTUS is a Phase 3 clinical research study for people aged 40-80 who have moderate to severe COPD and are currently being treated with standard of care therapy. The study medication, dupilumab, has not yet been approved by health authorities for COPD.

During the study, participants will receive either dupilumab or placebo as an injection once every 2 weeks. All study-related COPD medical care well as standard of care COPD medication will be covered at no cost. Compensation for time & travel may also be available for study participants.

You can learn more about this study here: Clincaltrials.gov.

Do you qualify for this study? You may be eligible if you are:

• Between the ages of 40 and 80 years of age
• A current or former smoker

Motivate others with your story!

If you have COPD and have benefited from Pulmonary Rehabilitation (PR), the COPD Foundation and Baystate Health invite you to share your experiences in this NIH-funded study to help motivate others to attend PR.

Share your story in a recorded 10-minute video call. Receive a $50 gift card for your time. To learn more, fill out this short contact form or contacts Raj Kotejoshyer, ScD, with Baystate Health at (413) 794-7909 or by email at rajashree.kotejoshyer@baystatehealth.org.

We are conducting a research study to learn more about stigma experienced by people with chronic obstructive pulmonary disease. As you may know, many people with COPD have experienced stigma and this can have a negative effect on their physical and mental health. The knowledge we gain from this research will be useful in developing and evaluating a questionnaire designed to measure COPD related stigma.

Approximately 300 people will participate in this research. We expect it to take about 20 minutes to complete the survey. If you decide to take part in the study, we’ll ask you to complete the online questionnaires.

You are eligible to take part in this study if:

• you are at least 45 years old
• you are diagnosed with or being told by your primary care provider that you have COPD, emphysema, or chronic bronchitis
• you are able to speak and read English as the first language

You are not eligible to take part in this research if:

• you are diagnosed with a mental illness, HIV/AIDS, lung cancer, or severe physical deformities.

Before beginning the questionnaire, please read the “Consent Form for a Research Project on Development and Psychometric Assessment of the COPD-Related Stigma Scale” at the top of the questionnaires, describing the purpose of this study, benefits and risks and procedures. All of your answers will be kept confidential. No one outside of the study team will be informed of your individual answers. You will receive a $10 gift card for completing this survey.

Thank you very much for your participation. If you have any questions about this study, please contact the principal investigator, Seoyoon Woo, by phone at 910-962-3843 or email at woos@uncw.edu.

The COPD Foundation is pleased to be able to share opportunities regarding research studies with COPD360social members. If you have any questions about this opportunity, please contact your physician or the link at the end of this post.

COPD patients take inhaled medicines (like ipratropium bromide and tiotropium) which help decrease mucus production and block reflexes produced by airway nerves that contribute to COPD symptoms.¹ Inhaled medicines can help patients manage their COPD symptoms, but are challenging for patients in several ways:

• Copays for COPD medications can be expensive
• Patients must remember to take their COPD medications every day as prescribed for them to work effectively
• Using the inhaler devices correctly and getting these medications into the smaller airways is difficult, particularly for people with poor lung function, i.e. people with COPD!

Over a three-year period, nearly 50% of patients with COPD will suffer at least one COPD flare-up despite taking their routine COPD inhalers¹. A COPD flare-up is when your COPD symptoms become much worse than normal, and you need to seek additional medical care. This happens when the COPD medications are overwhelmed by airway nerve activity, typically resulting from bacteria or viruses, and are unable to keep mucus low and airways open. Patients may need urgent care or may even be hospitalized, although most flare-ups can be managed with additional prescriptions, usually for steroids and/or antibiotics. However, these medications have worrisome side effects, especially with long-term use^2,3 . And COPD flare-ups worsen lung function, exercise tolerance and quality of life for weeks or even months, making it difficult for patients to recover.

The COPD Foundation is partnering with Collaboration in COPD Exacerbations (CICERO) and the European Lung Foundation(ELF) to ask patients to share their thoughts on questionnaires that have been developed to assess how COPD affects your daily life. We understand that questionnaires are sometimes long and difficult. We also want to hear your thoughts on how care can be improved.

Please visit the ELF website and share your story by taking the survey: https://europeanlung.org/en/get-involved/surveys/involving-patients-in-copd-research/

Before a medical device can be approved for use in a general population, a thorough process of research must be done. Clinical studies are one of the key steps in that process. Doctors are enrolling volunteers for a treatment in a clinical study that may have the potential to reduce COPD Flare-ups.

If you have COPD and still experience flare-ups despite your medications, you may qualify for the AIRFLOW-3 Clinical Trial. The trial is evaluating Targeted Lung Denervation, an investigational treatment which may have the potential to reduce the risk of COPD flare-ups through a one-time, non-surgical, outpatient procedure.

New COPD research can’t move forward without volunteers like you. Answer a few questions to see if you may be eligible to take part. Visit https://airflowtrial.com to complete a short survey.